BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

Now, the biotech has struck a deal to gain full control of PM8002, a bispecific also known as BNT327. BioNTech is paying $800 ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The acquisition is centered around Biotheus’ main asset, BNT327/PM8002, which works by boosting the immune system to attack ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

BNT327 has been tested in clinical trials with tumour patients, and Biotheus previously held the rights to commercialize it ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an ...

In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes. Last ...